‘Functional Cure‘ of HIV Infection: The Role of Immunotherapy
2012; Future Medicine; Volume: 4; Issue: 3 Linguagem: Inglês
10.2217/imt.12.2
ISSN1750-7448
Autores Tópico(s)Immune Cell Function and Interaction
ResumoImmunotherapyVol. 4, No. 3 Editorial'Functional cure' of HIV infection: the role of immunotherapyFelipe GarcíaFelipe GarcíaInfectious Diseases Unit, Hospital Clínic, Villarroel, 170, 08036 Barcelona, Spain. Published Online:8 Mar 2012https://doi.org/10.2217/imt.12.2AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: dendritic cellfunctional cureHIVimmunotherapytherapeutic vaccineReferences1 Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338(13),853–860 (1998).Crossref, Medline, Google Scholar2 Plana M, García F, Gallart MT et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS14,1921–1933 (2000).Crossref, Medline, CAS, Google Scholar3 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med.9(6),727–728 (2003).Crossref, Medline, CAS, Google Scholar4 Buzón MJ, Massanella M, Llibre JM et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med.16(4),460–465 (2010).Crossref, Medline, Google Scholar5 Plana M, García F, Gallart MT, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet352,1194–1195 (1998).Crossref, Medline, CAS, Google Scholar6 Gamberg J, Barret L, Bowmer M, Howley C, Grant M. Factors related to loss of HIV-specific cytotoxic T lymphocyte activity. AIDS18,597–604 (2004).Crossref, Medline, Google Scholar7 García F, Plana M, Vidal C et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS13,F79–F86 (1999).Crossref, Medline, CAS, Google Scholar8 Cohen J. New HIV infections drop, but treatment demands rise. Science330,1301 (2010).Crossref, Medline, CAS, Google Scholar9 Cohen J. The emerging race to cure HIV infections. Science332(6031),784–789 (2011).Crossref, Medline, CAS, Google Scholar10 Hutter G, Nowak D, Mossner M et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med.360(7),692–698 (2009).Crossref, Medline, CAS, Google Scholar11 Allers K, Hutter G, Hofmann J et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood117(10),2791–2799 (2011).Crossref, Medline, CAS, Google Scholar12 Karpas A, Hewlett IK, Hill F et al. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc. Natl Acad. Sci. USA87(19),7613–7617 (1990).Crossref, Medline, CAS, Google Scholar13 Abrams D, Levy Y, Losso MH et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med.361(16),1548–1559 (2009).Crossref, Medline, CAS, Google Scholar14 García F, Plana M, Ortiz GM et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS15,F29–F40 (2001).Crossref, Medline, CAS, Google Scholar15 García F, Plana M, Arnedo M et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions. A randomized study. AIDS17,43–51 (2003).Crossref, Medline, CAS, Google Scholar16 Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science305(5681),205–208 (2004).Crossref, Medline, CAS, Google Scholar17 Mocroft A, Reiss P, Gasiorowski J et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J. Acquir. Immune Defic. Syndr.55(2),262–270 (2010).Crossref, Medline, Google Scholar18 SMART Study Group. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med.355,2283–2296 (2006).Crossref, Medline, CAS, Google Scholar19 Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA284(17),2193–2202 (2000).Crossref, Medline, CAS, Google Scholar20 Gorse GJ, Simionescu RE, Patel GB. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1. Clin. Vaccine Immunol.13(1),26–32 (2006).Crossref, Medline, CAS, Google Scholar21 Dorrell L, Yang H, Iversen AK et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS19(12),1321–1323 (2005).Crossref, Medline, CAS, Google Scholar22 Papagno L, Alter G, Assoumou L et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS25(1),27–36 (2011).Crossref, Medline, CAS, Google Scholar23 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392(6673),245–252 (1998).Crossref, Medline, CAS, Google Scholar24 García F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine29(38),6454–6463 (2011).Crossref, Medline, CAS, Google Scholar25 Lu W, Arraes L, Ferreira W, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med.10,1359–1365 (2004).Crossref, Medline, CAS, Google Scholar26 García F, Climent N, Assoumou L et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis.203(4),473–478 (2011).Crossref, Medline, CAS, Google Scholar27 García F, Lejeune M, Climent N et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J. Infect. Dis.195,1680–1685 (2005).Crossref, Google Scholar28 Routy JP, Angel J, Vezina S et al. Final analysis of a Phase 2 study of an autologous DC immunotherapy (AGS-004) showed positive outcomes in primary endpoint of viral load control, and favorable safety and immunogenicity profile, in subjects undergoing structured treatment interruption of ART. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011 (Abstract 385).Google ScholarFiguresReferencesRelatedDetailsCited ByEffect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial11 November 2021 | Frontiers in Immunology, Vol. 12Optimal control strategy for the immunotherapeutic treatment of HIV infection with state constraint22 May 2019 | Optimal Control Applications and Methods, Vol. 40, No. 4Nonlinear Dynamical Systems in Modeling and Control of Infectious Disease3 September 2016Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluationEnrique Vacas-Córdoba, Núria Climent, Francisco J De La Mata, Montserrat Plana, Rafael Gómez, Marjorie Pion, Felipe García & Maria Ángeles Muñoz-Fernández22 December 2014 | Nanomedicine, Vol. 9, No. 17Promising Antibody Testing Strategies for Early Infant HIV Infection Diagnosis in China27 June 2014 | PLoS ONE, Vol. 9, No. 6Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?7 September 2012 | Retrovirology, Vol. 9, No. 1Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cureCurrent Opinion in Virology, Vol. 2, No. 5 Vol. 4, No. 3 Follow us on social media for the latest updates Metrics Downloaded 496 times History Published online 8 March 2012 Published in print March 2012 Information© Future Medicine LtdKeywordsdendritic cellfunctional cureHIVimmunotherapytherapeutic vaccineFinancial & competing interests disclosureThis study was partially supported by grants FIS PS09/01297, TRA-094, EC10-153, FIS PI10/02984 and SAF2006-26667-E from Red Temática Cooperativa de Grupos de Investigación en Sida (RIS) del Fondo de Investigación Sanitaria (FIS), HIV development program in Catalonia (HIVACAT) and Objectif recherche vaccin sida (ORVACS). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)